Search Results

You are looking at 1 - 8 of 8 items for :

  • "molecular testing" x
Clear All
Open access

Klaudia Zajkowska, Janusz Kopczyński, Stanisław Góźdź and Aldona Kowalska

tumour should be examined to exclude the presence of papillary structures. In addition, secondary criteria (molecular testing for BRAF V600E and other high-risk mutations and immunohistochemistry for BRAF V600E) were added that may be helpful but are

Open access

Barbora Pekova, Sarka Dvorakova, Vlasta Sykorova, Gabriela Vacinova, Eliska Vaclavikova, Jitka Moravcova, Rami Katra, Petr Vlcek, Pavla Sykorova, Daniela Kodetova, Josef Vcelak and Bela Bendlova

variants should also be detected, which could be another trigger of thyroid cancer. The genetic molecular testing seems to be the benefit for pediatric patients for their diagnosis and prognosis. Hopefully, it will improve the quality of life of pediatric

Open access

Natalie Rogowski-Lehmann, Aikaterini Geroula, Aleksander Prejbisz, Henri J L M Timmers, Felix Megerle, Mercedes Robledo, Martin Fassnacht, Stephanie M J Fliedner, Martin Reincke, Anthony Stell, Andrzej Januszewicz, Jacques W M Lenders, Graeme Eisenhofer and Felix Beuschlein

paraganglioma: molecular testing and personalized medicine . Current Opinion in Oncology 2016 28 5 – 10 . ( https://doi.org/10.1097/CCO.0000000000000249 ) 10.1097/CCO.0000000000000249 26599293 11 Favier J Amar L Gimenez-Roqueplo AP. Paraganglioma and

Open access

Ana Carolina de Jesus Paniza, Thais Biude Mendes, Matheus Duarte Borges Viana, Débora Mota Dias Thomaz, Paula B O Chiappini, Gabriel A Colozza-Gama, Susan Chow Lindsey, Marcos Brasilino de Carvalho, Venâncio Avancini Ferreira Alves, Otavio Curioni, André Uchimura Bastos and Janete Maria Cerutti

already proposed less aggressive treatment performed for benign lesions. To date, this evaluation cannot be replaced by preoperative molecular tests as the mutational profiling of this indolent category is still not completely understood, but the molecular

Open access

Dario de Biase, Federica Torricelli, Moira Ragazzi, Benedetta Donati, Elisabetta Kuhn, Michela Visani, Giorgia Acquaviva, Annalisa Pession, Giovanni Tallini, Simonetta Piana and Alessia Ciarrocchi

follicular thyroid cancer: current status and future directions . Molecular and Cellular Endocrinology 2010 322 8 – 28 . ( https://doi.org/10.1016/j.mce.2010.01.007 ) 6 Cappola AR Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status

Open access

Anello Marcello Poma, Riccardo Giannini, Paolo Piaggi, Clara Ugolini, Gabriele Materazzi, Paolo Miccoli, Paolo Vitti and Fulvio Basolo

-0288 20668010 25 Nikiforov YE Steward DL Robinson-Smith TM Haugen BR Klopper JP Zhu Z Fagin JA Falciglia M Weber K Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of

Open access

Luigi Laino, Silvia Majore, Nicoletta Preziosi, Barbara Grammatico, Carmelilia De Bernardo, Salvatore Scommegna, Anna Maria Rapone, Giacinto Marrocco, Irene Bottillo and Paola Grammatico

based on clinical and cytogenetic findings was revealed to be an important starting point to carry out the further appropriate molecular testing, specific for each DSD subgroup. Out of 88 patients, 7 (8%) were classified as 46,XX testicular DSD and

Open access

Ishita Gupta, Allal Ouhtit, Adil Al-Ajmi, Syed Gauhar A Rizvi, Hamad Al-Riyami, Marwa Al-Riyami and Yahya Tamimi

and/or carriers of benign tumors from January 2012 to April 2014 underwent biopsy and breast cancer surgery. Breast cancer was confirmed by biopsy reports as well as pathologically by molecular tests including estrogen receptor (ER), progesterone